Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression

BACKGROUND: Cancer targeting nanoprobes with precisely designed physicochemical properties may show enhanced pharmacological targeting and therapeutic efficacy. As a widely used commercialized antibody, rituximab has been in clinical use for three decades and has lengthened or even saved thousands o...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Lina, Zhang, Wei, Chen, Hong, Zhang, Xizhi, Wu, Haoan, Ma, Ming, Wang, Zhongqiu, Gu, Ning, Zhang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363495/
https://www.ncbi.nlm.nih.gov/pubmed/30787607
http://dx.doi.org/10.2147/IJN.S185458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363495/
https://www.ncbi.nlm.nih.gov/pubmed/30787607
http://dx.doi.org/10.2147/IJN.S185458

Ejemplares similares